Soleus Capital

Soleus Capital focuses on innovative life sciences — biotech, medtech, diagnostics, and genomics. The firm invests across the public-private boundary, targeting growth-stage, pre-IPO, PIPE, and complex recapitalization opportunities through a mix of equity, convertible, and structured instruments. The mandate avoids non-healthcare sectors entirely.

Soleus applies the same clinical and regulatory analytical framework to both private late-stage companies and publicly traded biotech or medtech firms. This allows the team to hold positions through market dislocations when the underlying scientific thesis remains unchanged, rather than reflexively selling on volatility. The firm often provides bridge capital before public listings or pivotal data readouts.

Soleus Capital has not publicly disclosed a total AUM figure or professional headcount. The firm maintains a lean operational structure and does not publish quarterly 13F holdings in a way that allows a complete reconstruction of assets, keeping its scale opaque to outside observers.

The firm deploys through direct equity, convertible notes, and structured financings. Soleus has a track record in PIPEs, recapitalizations, and pre-IPO rounds — transaction types that require evaluating both the clinical science and the near-term liquidity path. These structures position the firm as a provider of strategic capital during complex capital-markets windows for life-sciences companies.

Soleus invests primarily in North America and Western Europe, concentrating on regions with mature biotech and medtech innovation clusters and active public-markets infrastructure. The firm has not publicly signaled a material expansion into Asia-Pacific or other emerging life-sciences markets.